[1. Y. Zhijian, L. Hui, Y. Weiming, L. Zhanzhou, C. Zhong, Z. Jinxin, W. Hongyan, D. Xiangbin, Y. Weizhi, L. Duoyun, L. Xiaojun and D. Qiwen, Role of the aspartate transaminase and platelet ratio index in assessing hepatic fibrosis and liver inflammation in adolescent patients with HBeAg-positive chronic hepatitis B, Gastroenterol. Res. Pract. 2015 (2015) Article ID 906026 (6 pages); https://doi.org/10.1155/2015/90602610.1155/2015/906026450682426236336]Search in Google Scholar
[2. Q. Zhou and H. Tang, The progress of antiviral therapy in patients with HBV-related liver failure, Hepatogastroenterology 60 (2013) 1877-1880.]Search in Google Scholar
[3. S. Locarnini, Molecular virology of hepatitis B virus, Semin. Liver Dis. 24 (Suppl 1) (2004) 3-10.10.1055/s-2004-82867215192795]Search in Google Scholar
[4. Y. F. Liaw, Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy, Antivir. Ther. 11 (2006) 669-679.10.1177/135965350601100614]Search in Google Scholar
[5. Y. N. Ye and Z. L. Gao, Three attacks in the development of HBV-related liver failure, Infect. Dis. Inf. 22 (2009) 276-279; https://doi.org/10.3969/j.issn.1007-8134.2009.05.006]Search in Google Scholar
[6. S. Uemoto, Y. Inomata, T. H. Egawa, S. Fujita, T. Kiuchi, M. Hayashi, M. Yasutomi, H. Yamabe and K. Tanaka, Living donor liver transplantation for fulminant hepatic failure, Transplant. Proc. 42 (2010) 990-993; https://doi.org/10.18926/AMO/55435]Search in Google Scholar
[7. J. Gu, X. Shi, H. Ren, Q. Xu and J. Wang, Systematic review: extracorporeal bio-artificial liversupport system for liver failure, Hepatol. Int. 6 (2012) 670-683; https://doi.org/10.1007/s12072-012-9352-910.1007/s12072-012-9352-926201519]Search in Google Scholar
[8. M. K. Jain, L. Comanor, C. White, P. Kipnis, C. Elkin, K. Leung, A. Ocampo, N. Attar, P. Keiser and W. M. Lee, Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response, J. Viral Hepatitis 14 (2007) 176-182; https://doi.org/10.1111/j.1365-2893.2006.00797.x10.1111/j.1365-2893.2006.00797.x17305883]Search in Google Scholar
[9. Y. W. Kim, J. H. Kwon, E. Chung, S. W. Lee, J.-y. Lee, J. W. Jang, K. W. Chung and S. W. Nam, Short term virologic efficacies of telbivudine versus entecavir against hepatitis B-related hepatocellular carcinoma, Gastroenterol. Res. Pract. 2015 (2015) Article ID 181065 (7 pages); https://doi.org/10.1155/2015/18106510.1155/2015/181065438797325878659]Search in Google Scholar
[10. J. F. Zhang, Y. Guo, C. X. Chen, H. Y. Song, J. Dong, X. Chen, Z. L. Chen and B. Liu, A study on the treatment effect of telbivudine on hepatitis B patients with acute on chronic liver failure, Mil. Med. J. Southeast China (2016); https://doi.org/10.3760/cma.j.issn.1007-3418.2015.01.006]Search in Google Scholar
[11. S. S. Ma, Effect of enticavir on survival of patients with HBV-related liver failure: A meta-analysis, Shi Jie Hua Ren Xiao Hua Za Zhi (World Chin. J. Digestol.) 21 (2013) 2594-2600.10.11569/wcjd.v21.i25.2594]Search in Google Scholar
[12. B. Hutton, G. Salanti, D. M. Caldwell, A. Chaimani, C. H. Schmid, C. Cameron, J. P. A. Ioannidis, S. Straus, K. Thorlund, J. P. Jansen, C. Mulrow, F. Catalá-López, P. C. Gøtzsche, K. Dickersin, I. Boutron, D. G. Altman and D. Moher, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations, Ann. Intern. Med. 162 (2015) 777-784; https://doi.org/10.7326/m14-238510.7326/M14-238526030634]Search in Google Scholar
[13. C. P. Robert and G. Casella, Monte Carlo Statistical Methods, 2nd ed., Springer, New York, 2004.10.1007/978-1-4757-4145-2]Search in Google Scholar
[14. S. P. Brooks and A. Gelman, General methods for monitoring convergence of iterative simulations, J. Comput. Graph. Stat. 7 (1998) 434-455.10.1080/10618600.1998.10474787]Search in Google Scholar
[15. T. Kanda, M. Shinozaki, H. Kamezaki, S. Wu, S. Nakamoto, M. Arai, K. Fujiwara, N. Goto, F. Imazeki and O. Yokosuka, Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B, Int. J. Med. Sci. 9 (2012) 27-32.10.7150/ijms.9.27322208722211086]Search in Google Scholar
[16. B. Lin, C. Q. Pan, D. Xie, J. Xie, S. Xie, X. Zhang, B. Wu, C. Lin and Z. Gao, Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B, Hepatol. Int. 7 (2013) 460-467; https://doi.org/10.1007/s12072-012-9415-y10.1007/s12072-012-9415-y26201778]Search in Google Scholar
[17. L. J. Sun, J. W. Yu, Y. H. Zhao, P. Kang and S. C. Li, Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure, J. Gastroenterol. Hepatol. 25 (2010) 583-590; https://doi.org/10.1111/j.1440-1746.2009.06089.x10.1111/j.1440-1746.2009.06089.x]Search in Google Scholar
[18. L. Wang, H. Chen, C. Fan and Z. Gong, Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection, J. Med. Virol. 85 (2013) 1907-1912; https://doi.org/10.1002/jmv.2368910.1002/jmv.23689]Search in Google Scholar
[19. Y. Xianghui, X. Lang, Z. Yan, Z. Li, S. Xiaofeng and R. Hong, Prediction of prognosis to lamivudine in patients with spontaneous reactivation of hepatitis B virus-related acute-on-chronic liver failure: Using virologic response at week 4, Eur. J. Intern. Med. 25 ( 2014) 8 60-864; https://doi.org/10.1016/j.ejim.2014.10.00710.1016/j.ejim.2014.10.007]Search in Google Scholar
[20. T. Chen, Y. He, X. Liu, Z. Yan, K. Wang, H. Liu, S. Zhang and Y. Zhao, Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-onchronic liver failure, Clin. Exp. Med. 12 (2012) 159-164; https://doi.org/10.1007/s10238-011-0160-710.1007/s10238-011-0160-7]Search in Google Scholar
[21. Y. L. Cui, Y. Fang, Y. B. Wang, X. Q. Song, L. Li, X. Z. Lei, M. H. Zheng, T. Hong and F. Ping, Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection- associated acute or chronic liver failure, Dig. Dis. Sci. 55 ( 2010) 2 373-2380; https://doi.org/10.1007/s10620-010-1257-710.1007/s10620-010-1257-7]Search in Google Scholar
[22. H. Garg, S. K. Sarin, M. Kumar, V. Garg, B. C. Sharma and A. Kumar, Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure, Hepatology 53 (2011) 774-780; https://doi.org/10.1002/hep.2410910.1002/hep.24109]Search in Google Scholar
[23. K. Ma, W. Guo, M. Han, G. Chen, T. Chen, Z. Wu, D. Yang, J. Huang, Y. Huang, X. Zhao, J. Song, J. Qi and Q. Ning, Entecavir treatment prevents disease progression in HBV related acute-onchronic liver failure: Establishment of a novel logistical regression model, The International Liver Congress™ 201 - 46th annual meeting of the European Association for the Study of the Liver, Berlin, March 30 to April 3, 2011, Poster 742, J. Hepatol. 54 (Suppl. 1) (2011) S298; https://doi.org/10.1016/S0168-8278(11)60744-710.1016/S0168-8278(11)60744-7]Search in Google Scholar
[24. J. Lai, Y. Yan, L. Mai, Y. B. Zheng, W. Q. Gan and W. M. Ke, Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure, Hepatob. Pancreat. Dis. Int. 12 (2013) 154-159.10.1016/S1499-3872(13)60025-9]Search in Google Scholar
[25. Y. Zhang, X. Y. Hu, S. Zhong, F. Yang, T. Y. Zhou, G. Chen, Y. Y. Wang and J. X. Luo, Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure, World J. Gastroenterol. 20 (2014) 4745-4752; https://doi.org/10.3748/wjg.v20.i16.474510.3748/wjg.v20.i16.4745400051224782628]Search in Google Scholar
[26. J. Wang, K. Ma, M. Han, W. Guo, J. Huang, D. Yang, X. Zhao, J. Song, D. Tian and J. Qi, Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model, Hepatol. Int. 8 (2014) 64-71; https://doi.org/10.1007/s12072-013-9485-510.1007/s12072-013-9485-526202407]Search in Google Scholar
[27. J. Wang, J. Liu, C. Qi, T. Yan, F. Cao, L. Jin, Y. He, Y. Yang, S. Zhang, T. Chen and Y. Zhao, Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudineresistant HBV, Antivir. Ther. 20 (2015) 681-687; https://doi.org/10.3851/IMP298110.3851/IMP298126215771]Search in Google Scholar
[28. B. Ceylan, C. Yardimci, M. Fincanci, G. Eren, U. Tozalgan, C. Muderrisoglu and Y. Akkoyunlu, Comparison of tenofovir and entecavir in patients with chronic HBV infection, Eur. Rev. Med. Pharmacol. Sci. 17 (2013) 2467-2473.]Search in Google Scholar
[29. Y. B. Lee, E. U. Jung, B. H. Kim, J. H. Lee, H. Cho, H. Ahn, W. M. Choi, Y. Y. Cho, M. Lee and J. J. Yoo, Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B, Antimicrob. Agents Ch. 59 (2014) 972-978; https://doi.org/10.1128/AAC.04454-1410.1128/AAC.04454-14433586525421484]Search in Google Scholar
[30. Z. Krastev, D. Petrova, I. Kotzev, M. K. Celen, M. Mendelson, R. Chandra, P. Pandey and K. Hamed, Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study, World J. Hepatol. 8 (2016) 1402-1413; https://doi.org/10.4254/wjh.v8.i32.140210.4254/wjh.v8.i32.1402511447627917266]Search in Google Scholar
[31. P. Marcellin, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, New Engl. J. Med. 359 (2009) 2442-2455; https://doi.org/10.1056/NEJMoa080287810.1056/NEJMoa080287819052126]Search in Google Scholar
[32. V. Ratziu, V. Thibault, Y. Benhamou and T. Poynard, Successful rescue therapy with tenofovir in a patient with hepatic decompensation andesistant HBV mutant, Comp. Hepatol. 5 ( 2006) 1-4; https://doi.org/10.1186/1476-5926-5-110.1186/1476-5926-5-1136372816405720]Search in Google Scholar